Emergency medicine hinges on rapid, accurate triage — and nowhere is the margin for error smaller than when ruling out a heart attack. A growing body of clinical evidence suggests that the algorithms powering modern cardiac troponin testing may be far less reliable in actual emergency departments than the trial data implied, with consequences for millions of patients annually.
High-sensitivity cardiac troponin (hs-cTn) assays, deployed through accelerated 0h/1h or 0h/2h decision algorithms, were validated under carefully controlled study conditions using preselected patient populations. In real-world emergency settings, however, approximately 50% of patients tested fall into a diagnostic "gray zone" — neither clearly ruling in nor ruling out acute myocardial infarction (AMI). The positive predictive value for AMI drops substantially when the same decision thresholds are applied to older patients, those with impaired renal function, or those carrying pre-existing conditions like atrial fibrillation, heart failure, or established coronary artery disease. These comorbidities independently elevate troponin concentrations through non-ischemic mechanisms, confounding binary interpretation. Crucially, rule-in classifications frequently lead to hospital admission, yet discharge diagnoses regularly diverge from AMI.
This analysis highlights a fundamental translation gap between trial cohorts and clinical reality — a problem that extends well beyond cardiology. Renal insufficiency, for instance, reduces troponin clearance, producing chronically elevated baseline values that rapid-algorithm thresholds were not designed to accommodate. The review implicitly challenges the assumption that population-level sensitivity statistics are transferable to heterogeneous, unselected ED cohorts. The clinical implication is significant: over-triage driven by gray-zone results consumes hospital resources, exposes patients to unnecessary procedures, and may paradoxically delay care for non-cardiac emergencies. Improved individualized baseline comparators, age- and comorbidity-adjusted reference ranges, and clinician education on non-ACS troponin elevation represent the most promising mitigation strategies. This work is best characterized as a rigorous, confirmatory synthesis — not paradigm-shifting in isolation, but collectively urgent given the scale of misclassification it documents.